Related Experiment Video
Updated: Aug 6, 2026
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
A novel small molecule remyelination therapy for multiple sclerosis
Yan Yang1, Brain Bai2, Lars J S Knutsen3
1Department of Neurosciences, Cleveland Clinic, Cleveland, OH, USA.
Abstract:
We conducted a phenotypic screen of 20,000 central nervous system (CNS)-biased small molecules for their ability to stimulate differentiation of mouse oligodendrocyte progenitor cells (OPCs) into oligodendrocytes. We identified a lead hit (CN045) with an EC50 of 40 nM in the OPC differentiation assay and a chemical scaffold conducive to modifications. In OPC differentiation assays, CN045 demonstrated higher potency than a known OPC differentiation compound Triiodothyronine (T3). CN045 promoted myelin-like ensheathment of engineered nanofibers by mouse and human OPCs and significantly increased remyelination in white and gray matter regions of mouse brain following cuprizone/rapamycin-induced demyelination. In terms of pharmacokinetics, CN045 is CNS-penetrable with low cytotoxicity. CN045 has a short half-life in vivo, but its chemical scaffold is conducive to structural modifications that can improve its metabolic properties. Collectively, these results demonstrate that CN045 is an attractive lead candidate for enhancing OPC differentiation and remyelination in multiple sclerosis patients.
Insights
A novel compound, CN045, effectively stimulates oligodendrocyte progenitor cell (OPC) differentiation and promotes remyelination in the central nervous system (CNS). This discovery offers a promising therapeutic avenue for conditions like multiple sclerosis.
Area of Science:
- Neuroscience
- Cell Biology
- Pharmacology
Background:
- Oligodendrocyte progenitor cells (OPCs) are crucial for myelin repair in the central nervous system (CNS).
- Stimulating OPC differentiation is a key therapeutic strategy for demyelinating diseases such as multiple sclerosis.
- Existing compounds for OPC differentiation have limitations in potency or pharmacokinetic properties.
Purpose of the Study:
- To identify novel small molecules that promote OPC differentiation.
- To evaluate the efficacy of lead compounds in preclinical models of demyelination.
- To assess the pharmacokinetic properties and potential therapeutic applications of promising candidates.
Main Methods:
- Phenotypic screening of 20,000 CNS-biased small molecules for OPC differentiation activity.
- In vitro assays using mouse and human OPCs to determine compound potency (EC50) and efficacy.
- In vivo studies using a cuprizone/rapamycin-induced demyelination mouse model to assess remyelination.
- Pharmacokinetic analysis including CNS penetration and cytotoxicity assessment.
Main Results:
- A lead compound, CN045, was identified with high potency (EC50 = 40 nM) in stimulating OPC differentiation, outperforming Triiodothyronine (T3).
- CN045 induced myelin-like ensheathment of nanofibers by OPCs and significantly enhanced remyelination in demyelinated mouse brains.
- Pharmacokinetic studies confirmed CN045's CNS penetrability and low cytotoxicity, although it has a short in vivo half-life.
Conclusions:
- CN045 is a potent stimulator of OPC differentiation and a promising agent for promoting CNS remyelination.
- The chemical scaffold of CN045 allows for modifications to improve metabolic stability and in vivo half-life.
- CN045 represents an attractive lead candidate for developing new therapies for multiple sclerosis and other demyelinating disorders.
